Mostra el registre d'ítem simple
Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?
dc.contributor.author | Clotet, Bonaventura |
dc.contributor.author | Garolera, Maite |
dc.contributor.author | Muñoz Moreno, Jose A. |
dc.contributor.author | Fumaz, Carmina R. |
dc.contributor.author | Prats, Anna |
dc.contributor.author | Ferrer, Maria J. |
dc.contributor.author | Negredo, Eugènia |
dc.contributor.author | Pérez Álvarez, Nuria |
dc.contributor.author | Molto, Jose |
dc.contributor.author | Gómez Melis, Guadalupe |
dc.contributor.other | Universitat Politècnica de Catalunya. Departament d'Estadística i Investigació Operativa |
dc.date.accessioned | 2010-07-30T07:37:10Z |
dc.date.available | 2010-07-30T07:37:10Z |
dc.date.created | 2010-06 |
dc.date.issued | 2010-06 |
dc.identifier.citation | Muñoz, J. [et al.]. Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?. "Journal of neurovirology", Juny 2010, vol. 16, núm. 3, p. 208-218. |
dc.identifier.issn | 1355-0284 |
dc.identifier.uri | http://hdl.handle.net/2117/8480 |
dc.description.abstract | Because interruptions of antiretroviral treatment may entail clinical risks for human immunodeficiency virus (HIV)-infected individuals, we investigated their impact on neurocognitive functioning. Cross-sectional study was carried out, comparing HIV-infected persons who had interrupted antiretroviral therapy in the past (interruption group, IG) with persons who had never discontinued therapy (noninterruption group, NIG). Interruption was defined as the discontinuation of highly active antiretroviral therapy (HAART) for more than 15 days after previous treatment of at least 15 days. All the participants were on therapy. Demographic, clinical, and neurocognitive variables were assessed. The primary end point was the percentage of people with neurocognitive impairment. The score in different neurocognitive domains was a secondary end point. A total of 83 subjects participated in the study (IG: n = 27; NIG: n = 56). Demographic and clinical characteristics were balanced between the groups, except for years since HIV diagnosis (IG, 13.8; NIG, 10.2 [P = .003]). The percentage of people with neurocognitive impairment was significantly higher in the IG group (IG, 59.25%; NIG, 33.92% [P = 0.02]). As for scores in neurocognitive domains, individuals in the IG showed worse neurocognitive functioning, and significant differences in attention/working memory and information processing speed were found. The adjusted analysis supported the unadjusted analysis. In this study, a higher prevalence of neurocognitive impairment was detected in HIV-infected persons who had interrupted antiretroviral therapy in the past. Additionally, neurocognitive functioning was observed to be more impaired in the same individuals. Further studies should examine the potential negative effects of antiretroviral therapy interruptions on neurocognitive functioning. |
dc.format.extent | 11 p. |
dc.language.iso | eng |
dc.subject | Àrees temàtiques de la UPC::Ciències de la salut::Medicina |
dc.subject | Àrees temàtiques de la UPC::Matemàtiques i estadística::Estadística biosanitària |
dc.subject.lcsh | Highly active antiretroviral therapy |
dc.subject.lcsh | Mathematical statistics |
dc.subject.other | Antiretroviral therapy HIV infection Neurocognitive functioning Neuropsychological assessment Treatment interruption |
dc.title | Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning? |
dc.type | Article |
dc.subject.lemac | Sida -- Investigació |
dc.subject.lemac | Estadística matemàtica |
dc.contributor.group | Universitat Politècnica de Catalunya. GREMA - Grup de Recerca en Estadística Matemàtica i les seves Aplicacions |
dc.identifier.doi | 10.3109/13550281003767710 |
dc.subject.ams | Classificació AMS::62 Statistics::62P Applications |
dc.relation.publisherversion | http://www.ncbi.nlm.nih.gov/pubmed/20450380 |
dc.rights.access | Restricted access - publisher's policy |
local.identifier.drac | 2604573 |
dc.description.version | Postprint (published version) |
local.citation.author | Muñoz, J.; Fumaz, C.R.; Prats, A.; Ferrer, M.; Negredo, E.; Pérez, N.; Molto, J.; Gómez, G.; Garolera, M.; Clotet, B. |
local.citation.publicationName | Journal of neurovirology |
local.citation.volume | 16 |
local.citation.number | 3 |
local.citation.startingPage | 208 |
local.citation.endingPage | 218 |
Fitxers d'aquest items
Aquest ítem apareix a les col·leccions següents
-
Articles de revista [51]
-
Articles de revista [719]